News Article | May 19, 2017
BERLIN--(BUSINESS WIRE)--Le principal événement d’Europe concernant l’IdO sera de retour à Berlin dans seulement 2 semaines et il y a plein de domaines gratuits dans lesquels vous pourrez vous impliquer. Les 1er et 2 juin prochains, l’événement IoT Tech Expo explorera l’ensemble de l’écosystème de l'IdO, présentant les toutes dernières innovations technologiques dans le cadre de 6 thématiques de conférences, une zone pour les startups, 2 événements coimplantés couvrant la Blockchain et l’IA, une exposition présentant les toutes dernières innovations et la rencontre sur l’IdO. À savoir « Developing for the IoT » (Développer pour l’IdO), « IoT Innovations & Technologies » (Innovations et technologies pour l'IdO) et « Blockchain Technologies » (Technologies Blockchain) ; il s’agit d’une formidable occasion d’explorer le domaine plus large de l’IdO et de la Blockchain, et d’entendre tout un éventail de leaders de l’industrie travaillant pour des marques comme, entre autres, Volvo CE, Sigfox, Visa, Coca-Cola, BMW, Bluetooth, ESA, Allianz, Daimler, GSK, Metro et Johnson Controls. Avec plus de 200 exposants, dont les startups les plus innovantes, vous aurez l’occasion de voir les dernières technologies pour l’IdO, la Blockchain et l’IA en action, incluant, entre autres, les drones, les réfrigérateurs intelligents, la technologie de lecture des pensées, l’IA, l’impression 3D, la RV et la maintenance prédictive. Coimplantée avec la Blockchain Expo et l’AI Expo, vous pourrez y explorer de nombreux domaines nouveaux et enthousiasmants incluant, entre autres, l’apprentissage automatique, les robots, l'apprentissage profond et les analyses de données, couvrant des marchés verticaux allant de la finance à la musique en passant par l’immobilier, les soins de santé, les assurances et les administrations. Venez à la rencontre sur l’IdO (le 1er juin de 16h00 à 18h00) rencontrer des personnes ayant des affinités, construire des réseaux, partager des connaissances et développer de nouvelles opportunités commerciales. L’objectif est d’établir une communauté de personnes et d’organisations souhaitant collaborer, explorer et innover. Les sujets abordés incluent Industrie 4.0, le succès des startups et la Blockchain. Pourquoi ne pas vous y joindre ? Ce sont juste 7 des domaines gratuits auxquels vous pourrez participer lors de l’événement IoT Tech Expo Europe à Berlin les 1er et 2 juin ! Il vous suffit de vous inscrire pour obtenir votre laissez-passer GRATUIT pour l’exposition et faire l’expérience de tout ce qui vient d’être mentionné, et bien plus encore. L’IoT Tech Expo World Series (www.iottechexpo.com) accueille un contenu et des discussions de haut niveau, présentant et explorant les toutes dernières innovations dans le domaine de l'Internet des Objets (IdO). Elle réunit des secteurs clés, dont ceux de la fabrication, des transports, de la santé, de la logistique, du gouvernement, de l'énergie et de l'automobile.
News Article | May 16, 2017
Dublin, May 16, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Lyophilization Services for Biopharmaceuticals, 2017-2027" report to their offering. The Lyophilization Services for Biopharmaceuticals, 2017-2027' report provides an extensive study on the current market landscape of lyophilization services for biopharmaceuticals. The study presents an in-depth analysis of a diverse set of companies that provide such services across different regions worldwide. In fact, we identified close to 90 companies that are actively involved in providing lyophilization services for biopharmaceuticals. The study features a detailed analysis of the existing size and potential future growth opportunities (2017-2027) in the lyophilization services market for biopharmaceuticals. We have provided insights on the likely regional evolution of the market covering North America, Europe (UK, France, Italy, Spain, Germany and rest of Europe), Asia Pacific (Japan, China, India and South Korea) and rest of the world. In addition, we have provided the likely evolution and a market attractiveness analysis on the basis of the type of containment system (bulk containers, vials, syringes, ampoules and cartridges). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have presented three different forecast scenarios, depicting conservative, base and optimistic tracks of the market's evolution. The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. For the purpose of the study, we invited over 80 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities, challenges and likely future trends. The opinions and insights presented in this study were also influenced by discussions conducted with experts in this field. These included contributions from Steven Nail (Principal Scientist, Baxter BioPharma Solutions), Adam Viverette (Lyophilization Manager, Patheon), Patrick DePalma (Director, CMO Business Development, BioDefense Division, Emergent BioSolutions) and John Shaw (Head of Business Development and Marketing, Vibalogics). Key Topics Covered: 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION TO LYOPHILIZATION 3.1. Chapter Overview 3.2. Lyophilization: Historical Background 3.3. Lyophilization: Underlying Principle 3.4. Lyophilization: Equipment 3.5. Lyophilization: Advantages and Disadvantages 3.6. Lyophilization: Applications 4. LYOPHILIZATION OF BIOPHARMACEUTICALS 4.1. Chapter Overview 4.2. Need for Lyophilization of Biopharmaceuticals 4.3. Lyophilization Process for Biopharmaceuticals 4.4. Lyophilization Cycle Development and Optimization 4.5. Containment Systems Used for the Lyophilization of Biopharmaceuticals 5. COMPETITIVE LANDSCAPE 5.1. Chapter Overview 5.2. Lyophilization Service Providers for Biopharmaceuticals: Overall Landscape 5.3. Lyophilization Service Providers for Biopharmaceuticals: Analysis by Type of Biopharmaceuticals Lyophilized 5.4. Lyophilization Service Provides for Biopharmaceuticals: Analysis by Scale of Operation 5.5. Lyophilization Service Providers for Biopharmaceuticals: Analysis by Containment Systems 6. LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS: NORTH AMERICA 6.1. Chapter Overview 6.2. Anteco Pharma 6.3. Axcellerate Pharma 6.4. Berkshire Sterile Manufacturing 6.5. Emergent BioSolutions 6.6. LSNE Contract Manufacturing 6.7. Lyophilization Technology 6.8. Quality BioResources 6.9. North America: Lyophilization Services Market for Biopharmaceuticals, 2017-2027 (USD Million) 7. LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS: EUROPE 7.1. Chapter Overview 7.2. Amatsigroup 7.3. Biopharma Technology 7.4. Boehringer Ingelheim BioXcellence 7.5. LYOCONTRACT 7.6. Lyofal 7.7. Vetter Pharma 7.8. Europe: Lyophilization Services Market for Biopharmaceuticals, 2017-2027 (USD Million) 8. LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS: ASIA PACIFIC 8.1. Chapter Overview 8.2. BioZed Engineering 8.3. Bovogen Biologics 8.4. CinnaGen 8.5. Mycenax Biotech 8.6. Piramal Pharma Solutions 8.7. Samsung Biologics 8.8. Siam Bioscience 8.9. WuXi AppTec 8.10. Asia Pacific: Lyophilization Services Market for Biopharmaceuticals, 2017-2027 (USD Million) 8.10.1. Asia Pacific Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Containment System (USD Million) 9. MARKET SIZING AND FORECAST 9.1. Chapter Overview 9.2. Forecast Methodology 9.3. Lyophilization Services Market for Biopharmaceuticals, 2017-2027 (USD Million) 9.4. Lyophilization Services Market for Biopharmaceuticals, 2017-2027: Distribution by Region (USD Million) 9.5. Lyophilization Services Market for Biopharmaceuticals, 2017-2027: Distribution by Type of Containment System (USD Million) 10. BENCHMARK ANALYSIS 10.1. Chapter Overview 10.2. Benchmark Analysis: Methodology 10.3. Benchmark Analysis: Peer Groups 11. LYOPHILIZATION CYCLE DEVELOPMENT AND OPTIMIZATION 11.1. Chapter Overview 11.2. Lyophilization Cycle Development 11.3. Lyophilization Cycle Optimization 11.4. Lyophilization Cycle Development and Optimization: Service Providers 11.5. Lyophilization Cycle Development and Optimization Service Providers: Company Snapshots 12. ALTERNATIVE APPROACHES TO LYOPHILIZATION 12.1. Chapter Overview 12.2. Spray Drying 12.3. Spray Freeze Drying 12.4. Atmospheric Spray Freeze Drying 12.5. Vacuum Foam Drying 13. SURVEY ANALYSIS 13.1. Chapter Overview 13.2. Seniority Level of Respondents 13.3. Type of Biopharmaceuticals Lyophilized 13.4. Type of Containment System 13.5. Scale of Operation 13.6. Lyophilization Cycle Development and Optimization 13.7. Location of Lyophilization Facility 13.8. Likely Market Size 14. CONCLUSION 14.1. In Light of High Costs Associated with Establishing In-house Lyophilization Capabilities, Outsourcing has Emerged as a Convenient Alternative 14.2. Cycle Development and Optimization are Among the Key Lyophilization Processes; a Number of Players Specializing in These Services Have Entered the Market Expanding the Value Chain 14.3. Although Alternative Methods have Gained Attention in Recent Times, Lyophilization will Continue to Play a Pivotal Role 14.4. Fueled by the Growing Pipeline of Biopharmaceuticals, the Market is Likely to Witness Continuous Growth in the Coming Decade 15. INTERVIEW TRANSCRIPTS 15.1. Chapter Overview 15.2. Steven Nail, Principal Scientist, Baxter BioPharma Solutions 15.3. Adam Viverette, Lyophilization Manager, Patheon 15.4. Patrick DePalma, Director, CMO Business Development BioDefense Division, Emergent BioSolutions 15.5. John Shaw, Head of Business Development and Marketing, Vibalogics Companies Mentioned - AB BioTechnologies - Affinity Biologicals - Affinity Life Sciences - Ajinomoto - Albany Molecular Research (AMRI) - Alcami - Althea - Amatsigroup - Anteco Pharma - Apexigen - Aptevo Therapeutics - AusiaBio - Avrio Biopharmaceuticals - Axcellerate Pharma - Axys-Network - BSP Pharmaceuticals - Baccinex - Baxter BioPharma Solutions - Bayer Healthcare - Berkshire Sterile Manufacturing (BSM) - BioConnection - BioReliance - BioTechLogic - BioTechnique - BioZed Engineering - Biocon - Biopharma Technology - Bioserv Corporation - Biotechpharma - Biovian - Boehringer Ingelheim BioXcellence - Bovogen Biologicals - Bryllan - Burrard Pharmaceuticals - CARBOGEN AMCIS - CEPiA - CMC Biologics - Camurus - Canada Peptide - Capua BioServices - Catalent - Cenexi - CinnaGen - Clarity BioSolutions - Cobra Biologics - Coldstream Laboratories - Cook Pharmica - Corden Pharma - Coriolis Pharma - CuriRx - Dalton Pharma Services - DavosPharma - EUCODIS Bioscience - Emergent BioSolutions - Engineered Biopharmaceuticals - Eurogentec - FUJIFILM Diosynth Biotechnologies - Famar Health Care Services - Fedegari Group - Formurex - Fresenius Kabi Product Partnering - Frontage Labs - GILYOS (GIeseler LYOphilization Solutions) - GP Pharm - Gipharma - GlaxoSmithKline (GSK) - Goodwin Biotechnology - Grand River Aseptic Manufacturing (GRAM) - HALIX - HTD Biosystems - Hart Biologicals - Hovione - Hycult Biotech - IDIFARMA - IDT Biologika - Infectious Disease Research Institute (IDRI) - Integrity Bio - Jubilant HollisterStier - Jubilant Pharma - KABS Pharmaceutical Services - KBI Biopharma - Kamat Pharmatech - Kemwell Biopharma - LEUKOCARE - LSNE Contract Manufacturing - LYOCONTRACT - Legacy BioDesign - Lonza - Lyofal - Lyophilization Technology - MabPlex - Markt Technologies - MassDevelopment - Medicago - Micro-sphere - Miltenyi Biotec - Mycenax Biotech - NanoTools - National Institute of Allergy and Infectious Diseases (NIAID) - Nitto Avecia Pharma Services - Nova Laboratories - OctoPlus - Oncotec Pharma Produktion - OsoBio - PREMAS Biotech - PYRAMID Laboratories - PaizaBio - Particle Sciences - Patheon - Pfizer CentreOne - Pharmagen - Pharmatek - Pierre Fabre - Piramal Pharma Solutions - Praxair - Praxis Pharmaceutical - ProJect Pharmaceutics - Quality BioResources - Recipharm - Rentschler - SGS Group - SP Scientific - SYNERLAB Group - Samsung Biologics - Sanofi - Siam Bioscience - Singota Solutions - StemProtein - Symbiosis Pharmaceutical Services - SynCo Bio Partners - Syngene - The Native Antigen Company (NAC) - Therapure Biomanufacturing - Tofflon - Universal Stabilization Technologies - Upperton - Vectura - Vetter Pharma - Vibalogics - VxP Pharma - Wolfe Laboratories - WuXi AppTec For more information about this report visit http://www.researchandmarkets.com/research/46rmjf/lyophilization
News Article | May 18, 2017
— Blippar, the technology company building the world's first augmented reality browser through artificial intelligence and computer vision, today announced the launch of Augmented Reality Digital Placement (ARDP), the industry's first-ever AR digital ad unit. This new technology enables rich media units to leverage a user's smartphone and desktop camera to bring brand experiences to life without the need for a separate app. The ad unit delivers content and features designed to drive active engagement and interest in products, and is applicable to virtually every industry, including automotive, Entertainment, Retail and consumer-packaged goods. The technology will enable any advertiser, brand, agency, or digital publisher to deliver and scale interactive and contextually-relevant AR consumer experiences directly from digital banner ads. Augmented reality experiences are activated when the viewer clicks or taps on a call-to-action digital banner. ARDP can be launched from any rich media browser inventory on camera-equipped Android devices and via the Chrome browser on Desktop devices. The inventory will soon be accessible on iOS. ARDP extends the ability for brands and agencies to embrace the power of augmented reality and engage with consumers through diverse formats. This includes product packaging and digital ad banners today, and video and social media hashtags in the future. "It's exciting to see that advancements in augmented reality technology can now yield tangible campaigns for marketers," said Cary Tilds, chief innovation officer at GroupM. "Many of the most engaging AR formats today are limited to individual publishers or platforms, but Blippar's ARDP solution allows us to work in almost any camera-accessible web and mobile environment. That makes the issue of scaling exposure across publishers and audience segments much more simple. With contextual consumer targeting and data on the physical world in real-time, we're enabling our brands to understand more about their consumers' interests and behavior." The growth of the rich media market and investment in digital display advertisements show no signs of slowing down. According to a recent eMarketer forecast on US Ad Spending, display will continue to be the most popular digital ad format in 2017. Industry appetite for display advertisements and rich media suggests huge market opportunity for AR ad units in the US and worldwide. "From being a pioneer of AR six years ago, this latest launch shows that Blippar remains a leader in this technology, bringing further innovation to the digital ad industry," said Danny Lopez, Blippar Chief Operating Officer. "The app-agnostic nature of ARDP technology allows agencies and brands across all verticals to take advantage of the power of AR to build rich media experiences at scale and spur deeper consumer engagement." Blippar will work with agencies and brands to build AR rich media CPM campaigns with plans to have ARDP integrated with Blippar's self-service platform, Blippbuilder and Blippbuilder Script in the near future. About Blippar Blippar is a technology company that specializes in augmented reality (AR), computer vision and artificial intelligence (AI). Blippar's consumer product is the Blippar app, which is the first augmented reality browser, bridging the gap between digital and real-world experiences using AI and AR. The Augmented Reality app allows users to 'blipp' (scan) real-world items they are curious about -- from objects to buildings, animals and people -- to unlock useful and entertaining content. The content experiences are drawn from its proprietary knowledge graph or are augmented reality experiences created by Blippar and its partners. Blippar's AR technology has been used by world-leading brands such as PepsiCo, Porsche, Nestle, L'Oréal, GSK, General Mills and Procter & Gamble to create exciting and award-winning experiences which deepen consumer engagement. Blippar also offers enterprise solutions including Blippar's Computer Vision API and AR self-service creation tools, the Blippbuilder Suite. These are licensed to agencies and developers to create rich AR experiences at scale, including those with no coding skills. Blippar was named 9th most disruptive company in the world by CNBC in 2016. To learn more, visit blippar.com. For more information, please visit https://blippar.com/en/
News Article | May 18, 2017
Adding the injectable drug mepolizumab to standard treatment for eosinophilic granulomatosis with polyangiitis (EGPA), a rare immunologic disease, significantly improved clinical outcomes among participants in an advanced clinical trial, scientists report. The study was funded jointly by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the pharmaceutical company GSK, which makes mepolizumab. The trial took place at 31 research sites in nine countries, including the NIH Clinical Research Center in Bethesda, Maryland. Mepolizumab is already approved by the U.S. Food and Drug Administration to treat people with severe eosinophilic asthma. In EGPA, previously known as Churg-Strauss Syndrome, the number of a type of white blood cell called an eosinophil increases dramatically. People affected usually experience severe asthma first and later develop multi-organ damage as eosinophils accumulate in the walls of blood vessels. The eosinophils release toxic proteins that cause inflammation of and damage to blood vessel walls, leading to restricted blood flow and tissue damage. People with EGPA are currently treated with oral steroids, which usually must be taken continuously, but their long-term use has serious side effects. Additionally, the steroids do not help everyone, and relapses are common. To try to prevent recurrent relapses, doctors can add medications that suppress the immune system, but these drugs also can have serious side effects. In the Phase 3 clinical trial, scientists tested the efficacy of adding mepolizumab to steroid treatment for EGPA, with or without immunosuppressants, in 136 patients who either had not responded to treatment or had relapsed. For one year, half the participants received injections of mepolizumab and half received injections of a placebo every 4 weeks. Neither the investigators nor the participants knew who had received which until the end of the trial. EGPA was in remission cumulatively for at least 24 weeks in 28 percent of participants who received mepolizumab but in only 3 percent who received placebo. In addition, the disease was in remission at weeks 36 and 48 in 32 percent of participants who received mepolizumab but in only 3 percent who received placebo. Roughly half of participants who received mepolizumab did not achieve remission, compared to 81 percent of those who received placebo. An NIAID-funded study is under way to learn what biological markers distinguish those who benefitted from mepolizumab from those who did not. More information about the completed trial is available at ClinicalTrials.gov under study identifier NCT02020889. ME Wechsler et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. New England Journal of Medicine DOI: 10.1056/NEJMoa1702079 (2017). Alkis Togias, M.D., chief of the Allergy, Asthma, and Airway Biology Branch in the NIAID Division of Allergy, Immunology and Transplantation, is available for interviews. NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website. About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www. .